M&G Plc Has $408,000 Stock Position in Masimo Co. (NASDAQ:MASI)

M&G Plc increased its holdings in Masimo Co. (NASDAQ:MASIFree Report) by 4.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,240 shares of the medical equipment provider’s stock after acquiring an additional 149 shares during the period. M&G Plc’s holdings in Masimo were worth $408,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in MASI. Wells Fargo & Company MN lifted its holdings in shares of Masimo by 282.0% in the fourth quarter. Wells Fargo & Company MN now owns 116,712 shares of the medical equipment provider’s stock valued at $13,680,000 after purchasing an additional 86,162 shares in the last quarter. State Board of Administration of Florida Retirement System raised its holdings in shares of Masimo by 11.6% in the first quarter. State Board of Administration of Florida Retirement System now owns 54,839 shares of the medical equipment provider’s stock valued at $8,053,000 after purchasing an additional 5,688 shares during the last quarter. Quadrant Capital Group LLC lifted its position in shares of Masimo by 99.0% during the fourth quarter. Quadrant Capital Group LLC now owns 1,389 shares of the medical equipment provider’s stock valued at $163,000 after purchasing an additional 691 shares in the last quarter. Advisors Asset Management Inc. boosted its holdings in Masimo by 32.1% during the first quarter. Advisors Asset Management Inc. now owns 9,009 shares of the medical equipment provider’s stock worth $1,323,000 after purchasing an additional 2,187 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Masimo by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 4,781,343 shares of the medical equipment provider’s stock worth $560,421,000 after purchasing an additional 26,473 shares in the last quarter. Institutional investors own 85.96% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Piper Sandler lifted their target price on shares of Masimo from $160.00 to $165.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Wednesday, August 7th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $144.67.

Read Our Latest Analysis on Masimo

Masimo Stock Performance

NASDAQ:MASI opened at $128.39 on Wednesday. The company has a market capitalization of $6.83 billion, a P/E ratio of 87.34 and a beta of 0.97. The business has a fifty day simple moving average of $118.82 and a two-hundred day simple moving average of $127.91. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.31 and a quick ratio of 1.31. Masimo Co. has a 1 year low of $75.22 and a 1 year high of $153.93.

Masimo (NASDAQ:MASIGet Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.09. The company had revenue of $496.30 million during the quarter, compared to analyst estimates of $493.92 million. Masimo had a return on equity of 13.26% and a net margin of 4.01%. The firm’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.62 EPS. On average, analysts expect that Masimo Co. will post 3.63 earnings per share for the current year.

Masimo Profile

(Free Report)

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

Featured Stories

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.